Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Market Cap	$2.11B	P/E Ratio	N/A
52W High	$16.44	52W Low	$6.23
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-15.6%	52W Position	28.6%
Overall Score	40	Value Score	60
Quality Score	50	Technical Score	10

EPS Current Est	$-1.56	EPS Next Est	$-1.35
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OCUL	$9.15	+7.14%	3.38M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OCUL	$9.15	+7.1%	3.38M
3
4
5
6

OCUL

OCUL

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Ocular Therapeutix Inc. Data in Excel

Get Ocular Therapeutix Inc. Data in Excel